Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.40 |
| ▸ | AKT2 | P31751 | 5/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTGFR | P43088 | 4/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717045 | 0.90 | PIK3CB (0.40) | CYP3A4CYP2C9TSHRPIK3CD | |
| SCHEMBL713901 | 0.89 | AKT1 (0.43) | AKT1AKT2AKT3CYP3A4FABP3 | |
| SCHEMBL715607 | 0.89 | CNR2 (0.43) | PIK3CDCNR2 | |
| SCHEMBL716476 | 0.88 | CNR1 (0.40) | CYP2C9TSHRCASP1CASP7CNR2 | |
| SCHEMBL716682 | 0.87 | MAPT (0.48) | ALOX15TSHRCNR2 | |
| SCHEMBL715574 | 0.86 | STK4 (0.41) | TSHRCNR2 | |
| SCHEMBL715103 | 0.86 | KDM4E (0.39) | CNR2 | |
| SCHEMBL715705 | 0.86 | KDM4E (0.39) | CNR2 | |
| SCHEMBL715104 | 0.86 | KDM4E (0.39) | CNR2 | |
| SCHEMBL17530837 | 0.85 | ADRA2A (0.34) | AKT1AKT2AKT3PTGFRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
| EP-2403847-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100405-A1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | AKT1 297/4885AKT2 278/4885AKT3 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.